Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "bone-metastasis"

2 News Found

Biocon receives Health Canada approval for Bosaya and Vevzuo biosimilars to Prolia and Xgeva
Biopharma | April 24, 2026

Biocon receives Health Canada approval for Bosaya and Vevzuo biosimilars to Prolia and Xgeva

Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions

Biocon launches denosumab biosimilars Bosaya and Aukelso in US market
Biopharma | April 08, 2026

Biocon launches denosumab biosimilars Bosaya and Aukelso in US market

Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market

Latest Stories

Takara Bio, Resistomap join forces to streamline AMR surveillance from environmental samples

New genomics clinic by Fortis Hospitals targets early disease detection

Rossari Biotech reviews capex, delays Unitop and Tristar expansion rollout

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Ganesh Bade Director Bioprocessing–IMEA, Avantor
We believe in trust-driven clinical conversations to cut through medical misinformation: Saurav Kasera, Founder, CLIRNET
We believe in trust-driven clinical conversations to cut through medical misinformation: Saurav Kasera, Founder, CLIRNET
Saurav Kasera Founder, CLIRNET
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Packaging